Today News Journal
    What's Hot

    Trump Isn’t Touting His Biggest Success

    February 5, 2023

    The Colorado River Is Disappearing. Here’s How to Replenish It.

    February 5, 2023

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Today News Journal
    Contact Us
    • Home
    • Trending
    • Business
    • Health
    • Technology
      • Automobile
      • Gadgets
      • Mobiles
      • Robotics
    • Lifestyle
      • Culture
    • Sports
    • Travel
    • Editorials
    • News
      • Politics
    Today News Journal
    Home » Health » CDC advisers mull what’s next for Covid-19 boosters
    Health

    CDC advisers mull what’s next for Covid-19 boosters

    James MartinBy James MartinApril 22, 2022No Comments5 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    “Policy around future doses require continued evaluation of Covid-19 epidemiology and vaccine effectiveness, including the impact of both time and variants, and the ability of doses to improve this protection,” the CDC’s Dr. Sara Oliver, an epidemic intelligence service officer with the Division of Viral Diseases, said at the meeting.

    Before recommending future doses of Covid-19 vaccines, Oliver said, the committee members would need to assess the nation’s recent case counts, hospitalization rates, vaccine effectiveness — including whether it’s waning over time — and the impacts of circulating coronavirus variants.

    As the virus continues to evolve, the “evolution of the Covid vaccines will be important,” including the vaccine platforms, Oliver said.

    The Covid-19 vaccinations that people get in the future could be completely different formulations from what’s being given now, which is based on the original version of the virus that emerged in late 2019.

    The next booster might be a new vaccine

    Some companies, including Pfizer/BioNTech and Moderna, are developing variant-specific vaccines that could target whatever strain of the coronavirus is circulating when that booster might be needed. Pfizer and Moderna are working on vaccines that would specifically protect against the Omicron variant, even though it’s not clear whether one is needed.

    The time needed to manufacture a vaccine — once it is decided to change or update the composition of that vaccine — also is not clear.

    But for the vaccines that are now available, a decision to modify them would need to be made “at the latest by the beginning of the summer” if a vaccination campaign were to be needed in the fall, Dr. Doran Fink, deputy director of the US Food and Drug Administration’s Division of Vaccines, said at Wednesday’s meeting.

    FDA vaccine advisers say a plan for updating Covid-19 shots is needed
    Pfizer CEO Albert Bourla has said the company is also hoping to make a vaccine that will protect against Omicron as well as all other variants of the coronavirus.

    The goal is to create “something that can protect for at least a year,” Bourla told CBS in March. “And if we are able to achieve that, then I think it is very easy to follow and remember so that we can go back to really the way [we] used to live.”

    Moderna announced Tuesday that its first bivalent Covid-19 booster shot candidate — which combines elements of the current vaccine with updates based on the Beta variant — induced higher antibody responses against all variants of concern than the company’s original Covid-19 booster.

    Moderna has been developing updated booster candidates to target emerging coronavirus variants, and it also has monovalent (based on a single virus strain) candidates in the works.

    Its first bivalent booster candidate, called mRNA-1273.211, was well-tolerated, the company said, and a preprint study posted last week to the online server Research Square found that it elicited higher antibody responses than Moderna’s current booster shot against the original coronavirus and the Beta, Delta and Omicron variants.

    Moderna scientists wrote in the study that the safety profile of a 50-microgram dose of the mRNA.1273.211 booster candidate was comparable to that of the current 50-microgram dose of vaccine.

    The study has not been peer-reviewed or published in a professional journal.

    Despite the booster candidate’s superiority over the original vaccine, Moderna CEO Stéphane Bancel said in a news release Tuesday that a separate bivalent candidate combining the current vaccine with an Omicron-specific one is still the company’s lead candidate to possibly roll out this fall.

    Two-in-one flu-Covid vaccines in development

    Moderna and the biotechnology company Novavax also are working on two-in-one combination vaccines that can offer protection against both flu and Covid-19.

    Novavax seeks FDA emergency use authorization of its coronavirus vaccine

    Novavax’s Covid-19 vaccine is not authorized in the United States, but the company submitted a request for emergency use authorization to the US Food and Drug Administration in January.

    In the meantime, it continues to study the vaccine that combines its NVX-CoV2373 Covid-19 vaccine and its quadrivalent flu vaccine candidate. On Wednesday, Novavax announced that the combination vaccine was “well-tolerated” and induced an immune response among participants in a Phase 1/2 clinical trial.

    Novavax scientists assessed the safety of different formulations of the vaccine as well as the immunological responses they induced. The trial data showed that the combination vaccine induced immune responses comparable to those induced when the flu vaccine and Covid-19 vaccine are given separately.

    A fourth Covid-19 shot might be recommended this fall, as officials 'continually' look at emerging data

    The data also showed that the safety profile of the combination vaccine was consistent with the standalone safety profiles of the flu and Covid-19 vaccines. Serious adverse events in the trial were “rare and none were assessed as being related to the vaccine,” the company said.

    “We continue to evaluate the dynamic public health landscape and believe there may be a need for recurrent boosters to fight both COVID-19 and seasonal influenza,” Dr. Gregory Glenn, Novavax’s president of research and development, said in a news release. “We’re encouraged by these data and the potential path forward.”

    Novavax announced that the data supports advancing the study to a Phase 2 trial, which is expected to begin by the end of the year.

    For now, the CDC’s vaccine advisers plan to continue discussions around how to “be more proactive than reactive” when it comes to the future need for Covid-19 vaccinations, Dr. Matthew Daley, chair of the committee’s vaccine working group and senior investigator at the Kaiser Permanente Institute for Health Research, said in Wednesday’s meeting.

    “These are our marching orders,” Daley told his fellow committee members.

    “We had plenty on our plate before, but then we want to take what we’ve heard in this meeting and take it to the work group and discuss each and every one of these issues,” he said. “Given the unpredictability of the pandemic, we’ve needed to be reactive, but I think this is a place where we can also try to be more proactive.”



    Source link

    Related posts:

    1. Covid vaccine ‘Mix of science and politics’ leading to uncertainty, NIH director says
    2. The FDA authorizes more e-cigarette products, but there’s still no ruling on menthol and other kid-friendly nicotine products
    3. Wastewater monitoring for Covid-19 is picking up steam across the US
    4. Studies show lasting effects of gun violence, possible interventions
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleHull FC and Hull KR stars named in Ellery Hanley’s Combined Nations All Stars squad
    Next Article STD symptoms: Painful bowel movements may indicate gonorrhoea
    James Martin
    • Website

    Related Posts

    How to be prepared in case of a shooting without living in fear

    January 26, 2023

    Many women underestimate breast density as a risk factor for breast cancer, study shows

    January 26, 2023

    Pediatricians are giving out free gun locks to approach the gun violence epidemic as a public health crisis

    January 25, 2023

    CDC figuring out ‘logistical and legal’ aspects of testing airplane wastewater for coronavirus variants, source says

    January 25, 2023

    Leave A Reply Cancel Reply

    Search
    Categories
    • Automobile
    • Business
    • Coronavirus
    • Culture
    • Editorials
    • Finance
    • Gadgets
    • Health
    • Lifestyle
    • Mobiles
    • Money
    • News
    • Politics
    • Sports
    • Technology
    • Travel
    • Trending
    • World
    Latest Posts

    Trump Isn’t Touting His Biggest Success

    February 5, 2023

    The Colorado River Is Disappearing. Here’s How to Replenish It.

    February 5, 2023

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023
    • Facebook
    • Twitter
    Don't Miss
    News

    Trump Isn’t Touting His Biggest Success

    By James MartinFebruary 5, 20230

    Comment on this storyCommentOne sunny spring morning in May 2020, President Donald Trump stood in…

    The Colorado River Is Disappearing. Here’s How to Replenish It.

    February 5, 2023

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023

    Here’s How Finland, Sweden and NATO Should Deal With Erdogan

    February 5, 2023
    • Facebook
    • Twitter
    About Us

    Hello friends, I am James Martin. Welcome to my blog todaynewsjournal.com. We are a team of experienced journalists who are passionate about delivering the latest news and current events to our readers. Our editorial team is dedicated to providing the most accurate and up-to-date information possible. We aim to be your go-to source for news and current events. Here on this site, You will get up to date information regarding all important categories like business ideas, health tips,... (Read More)

    Latest News

    Trump Isn’t Touting His Biggest Success

    February 5, 2023

    The Colorado River Is Disappearing. Here’s How to Replenish It.

    February 5, 2023

    Fake Meat’s Beyond Impossible Quest to Win Over Americans

    February 5, 2023
    SIGN UP NEWSLETTER

    Join The Conversation sign up to receive emails for The Daily special tips general info.

      Facebook Twitter Instagram Pinterest
      • Home
      • Editorials
      • Get In Touch

      Copyright © 2021-2023 · Today News Journal Privacy Policy

      Type above and press Enter to search. Press Esc to cancel.

      We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
      Cookie SettingsAccept All
      Manage consent

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
      Necessary
      Always Enabled
      Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
      CookieDurationDescription
      cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
      cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
      cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
      cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
      cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
      viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
      Functional
      Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
      Performance
      Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
      Analytics
      Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
      Advertisement
      Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
      Others
      Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
      SAVE & ACCEPT

      Sign In or Register

      Welcome Back!

      Login to your account below.

      Lost password?